# A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)

> **NCT01458535** · PHASE2 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 61 (actual)

## Conditions studied

- Hepatitis C Virus

## Interventions

- **DRUG:** ABT-450
- **DRUG:** ABT-267
- **DRUG:** ribavirin
- **DRUG:** ritonavir

## Key facts

- **NCT ID:** NCT01458535
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2016-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01458535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01458535, "A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01458535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*